Repligen Corp (RGEN)
NASDAQ:RGEN

Repligen (RGEN) Stock Price & Analysis

874 Followers

RGEN Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$137.21 - $262.26
Previous Close$167.58
Volume286.86K
Average Volume (3M)568.51K
Market Cap
$9.28B
Enterprise Value$9.08B
Total Cash (Recent Filing)$623.76M
Total Debt (Recent Filing)$422.96M
Price to Earnings (P/E)51.8
Beta1.60
Apr 26, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.24
Shares Outstanding55,562,583
10 Day Avg. Volume555,005
30 Day Avg. Volume568,514
Standard Deviation0.11
R-Squared0.26
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)12.69
Price to Sales (P/S)11.11
Price to Cash Flow (P/CF)53.50
P/FCF Ratio210.70
Enterprise Value/Market CapN/A
Enterprise Value/Revenue11.33
Enterprise Value/Gross Profit19.93
Enterprise Value/Ebitda33.47
Forecast
Price Target Upside30.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8


Financials

Annual

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

RGEN FAQ

What was Repligen Corp’s price range in the past 12 months?
Repligen Corp lowest stock price was $137.21 and its highest was $262.26 in the past 12 months.
    What is Repligen Corp’s market cap?
    Currently, no data Available
    When is Repligen Corp’s upcoming earnings report date?
    Repligen Corp’s upcoming earnings report date is Apr 26, 2023 which is in 28 days.
      How were Repligen Corp’s earnings last quarter?
      Repligen Corp released its earnings results on Feb 22, 2023. The company reported $0.68 earnings per share for the quarter, beating the consensus estimate of $0.577 by $0.103.
        Is Repligen Corp overvalued?
        According to Wall Street analysts Repligen Corp’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Repligen Corp pay dividends?
          Repligen Corp does not currently pay dividends.
          What is Repligen Corp’s EPS estimate?
          Repligen Corp’s EPS estimate is $0.59.
            How many shares outstanding does Repligen Corp have?
            Repligen Corp has 55,562,584 shares outstanding.
              What happened to Repligen Corp’s price movement after its last earnings report?
              Repligen Corp reported an EPS of $0.68 in its last earnings report, beating expectations of $0.577. Following the earnings report the stock price went down -4.506%.
                Which hedge fund is a major shareholder of Repligen Corp?
                Among the largest hedge funds holding Repligen Corp’s share is Sands Capital Management LLC. It holds Repligen Corp’s shares valued at 302M.

                  ---

                  Repligen Stock Smart Score

                  The Repligen stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Repligen Corp

                  Repligen Corp. provides advanced bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. The firm serves through the following product lines: Chromatography; Filtration; and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The OEM products are represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification, and cell culture growth factor products. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.

                  ---

                  Top 5 ETFs holding RGEN

                  Name
                  Market Value
                  Smart Score
                  iShares Biotechnology ETF
                  8
                  VanEck Biotech ETF
                  8
                  Invesco Dynamic Biotechnology & Genome ETF
                  8
                  First Trust Hedged BuyWrite Income ETF
                  8
                  Up to five ETFs with an Outperform Smart Score that hold RGEN. The ETFs are listed according to market value of RGEN within the ETF

                  ---

                  Forecast EPS vs Actual EPS


                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Avantor
                  Bio-Techne
                  Charles River Labs
                  Bio-Rad Laboratories
                  Bruker

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis